Title:
KINESIN KIF18A INHIBITOR AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2023/217233
Kind Code:
A1
Abstract:
Provided are a compound having a structure of formula (I) or a pharmaceutically acceptable salt, a stereoisomer, an isotope isomer, a prodrug, a hydrate or a solvate thereof. The compound is capable of modulating the KIF18A protein, thereby affecting the cell cycle and cell proliferation process to treat cancer and cancer-related diseases. Further provided are a method for synthesizing the compound, a pharmaceutical composition containing the compound, and a method for treating a condition related to the activity of KIF18A.
Inventors:
XIAO YISONG (CN)
GU XIAOHUI (CN)
LAI KUNMIN (CN)
GU XIAOHUI (CN)
LAI KUNMIN (CN)
Application Number:
PCT/CN2023/093541
Publication Date:
November 16, 2023
Filing Date:
May 11, 2023
Export Citation:
Assignee:
SHANGHAI APEIRON THERAPEUTICS COMPANY LTD (CN)
International Classes:
C07D401/14; A61K31/455; A61K31/495; A61K31/63; A61P35/00; C07D401/04; C07D401/12; C07D405/04
Foreign References:
| CN113226473A | 2021-08-06 | |||
| CN114269731A | 2022-04-01 | |||
| CN114302880A | 2022-04-08 | |||
| CN114391012A | 2022-04-22 | |||
| CN114401953A | 2022-04-26 | |||
| US20220002311A1 | 2022-01-06 | |||
| US20220056015A1 | 2022-02-24 | |||
| US20220073504A1 | 2022-03-10 |
Attorney, Agent or Firm:
UNITALEN ATTORNEYS AT LAW CO., LTD. (CN)
Download PDF:
Previous Patent: KINESIN KIF18A INHIBITOR AND USE THEREOF
Next Patent: LIQUID ANTIBODY COMPOSITION AND USE THEREOF
Next Patent: LIQUID ANTIBODY COMPOSITION AND USE THEREOF